Achaogen (NASDAQ: AKAO) is one of 292 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Achaogen to similar businesses based on the strength of its analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.
Risk & Volatility
Achaogen has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Achaogen’s rivals have a beta of 6.66, meaning that their average share price is 566% more volatile than the S&P 500.
This table compares Achaogen and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
84.2% of Achaogen shares are owned by institutional investors. Comparatively, 50.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.4% of Achaogen shares are owned by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Achaogen and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Achaogen||$35.51 million||-$68.05 million||-4.24|
|Achaogen Competitors||$258.58 million||$65.85 million||-7.43|
Achaogen’s rivals have higher revenue and earnings than Achaogen. Achaogen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent recommendations for Achaogen and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Achaogen presently has a consensus target price of $28.13, indicating a potential upside of 110.04%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 30.56%. Given Achaogen’s stronger consensus rating and higher probable upside, research analysts clearly believe Achaogen is more favorable than its rivals.
Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company’s Early Development programs include C-Scape and LpxC.
What are top analysts saying about Achaogen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Achaogen Inc. and related companies.